Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $30.3600 (8.7%) ($30.3600 - $30.3600) on Tue. Dec. 8, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.32% (three month average) | RSI | 54 | Latest Price | $30.3600(8.7%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 1.6% a day on average for past five trading days. | Weekly Trend | TGTX declines -2.5% a week on average for past two weeks. | Market Behavior | Value stock rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(64%) ARKG(60%) ARKK(56%) IBB(56%) IWO(56%) | Factors Impacting TGTX price | TGTX will decline at least -1.66% in a week (0% probabilities). VIXM(-37%) VXX(-34%) UUP(-19%) TBT(-2%) UNG(-0%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.66% (StdDev 3.32%) | Hourly BBV | 1.7 () | Intraday Trend | 0% | | | |
|
Inflection Point | Yes | 5 Day Moving Average | $28.38(6.98%) | 10 Day Moving Average | $28.86(5.2%) | 20 Day Moving Average | $29(4.69%) | To recent high | -2.5% | To recent low | 28% | Market Cap | $3.845b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |